MedTrace Logo

Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes

NCT00898950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2009-05-12

No results posted yet for this study

Summary

This study was set up to assess the effects of different doses of aspirin when compared with placebo (dummy drug), used sequentially over a 2 week study period with a 2 week wash-out (rest period) in between, in people with type-2 diabetes and high cardiovascular risk. Specifically, its effects on different factors which are thought to contribute to diabetes such as insulin resistance (body's ability to effectively use insulin), dysglycaemia (excess glucose in the blood), oxidative stress (effects from accumulation of by-products of metabolism), endothelial function (function of lining of blood vessels) and inflammation were studied.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Aspirin

Aspirin 75mgs/day orally for 2 weeks.

DRUG

Aspirin

300mgs/day orally for 2 weeks

DRUG

Aspirin

aspirin 900mgs QID orally for 2 weeks

OTHER

placebo tablet

placebo tablet with lactose and excipients.

Sponsors & Collaborators

  • University of Portsmouth

    lead OTHER

Principal Investigators

  • Rajeev P Raghavan, MBBS, MRCP · Portsmouth Hospitals NHS Trust

  • Michael H Cummings, MD, FRCP · Portsmouth Hospitals NHS TRust & University of Portsmouth

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898950 on ClinicalTrials.gov